FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20040

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cousins Bruce						2. Issuer Name and Ticker or Trading Symbol Arbutus Biopharma Corp [ABUS]							of Reporting cable) or (give title	g Persor	n(s) to Issu 10% Ow Other (s)	ner
(Last) (First) (Middle) C/O ARBUTUS BIOPHARM CORP. SUITE 100, 8900 GLENLYON PARKWAY					3. Date of Earliest Transaction (Month/Day/Year) 07/09/2015							X Officer (give title Other (specify below) EVP & CFO				
(Street) BURNABY A1 V5J 5J8					4. If Amendment, Date of Original Filed (Month/Day/Year) 12/22/2015							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				ansaction	n ear)	2A. Deemed Execution Date, if any (Month/Day/Year		3. Transaction	4. Secur	4. Securities Acquired (A) Disposed Of (D) (Instr. 3,		5. Amou Securitie Beneficia Owned F	nt of es ally Following	6. Owner Form: D (D) or Ir (I) (Instr	Direct condirect E r. 4) C	7. Nature of Indirect Beneficial Ownership
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a				nstr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transaction Code (Insti				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly O	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$17.57	07/09/2015		A		75,000		(1)	03/30/2025	Common Shares	75,000	\$0	75,000)	D	

Explanation of Responses:

1. The option vests as follows: 1/3 on 3/30/2016; 1/3/ on 3/30/2017; and 1/3 on 3/30/2018.

Remarks:

 $2.\ Form\ 4$ amendment is being filed solely to correct the title of the reporting person.

<u>/s/ Bruce Cousins</u> <u>12/28/2015</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.